🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ctDNA

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma NCT06606028n/a1 site📍 San Francisco University of California, San Francisco · Tests: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408n/a1 site📍 Shanghai RenJi Hospital · Tests: Adjuvant chemotherapy, adjuvant immunotherapy Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma NCT07223541Phase 21 site📍 Oklahoma City University of Oklahoma · Tests: Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution ctDNA Assay in Patients With Resectable Pancreatic Cancer NCT05052671n/a2 sites📍 Oklahoma City📍 Tulsa University of Oklahoma Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma NCT07516678n/a1 site📍 Guangzhou Sun Yat-sen University Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial NCT07726602n/a1 site📍 Portland OHSU Knight Cancer Institute · Tests: Non-Interventional Study Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan NCT06358222n/a1 site📍 Shanghai Shanghai Chest Hospital · Tests: Blood ctDNA + methylation + PET-CT and Postoperative pathology, MRD+ methylation (or combined with PET-CT) and Invasive… Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354n/a1 site📍 Palo Alto Adaptive Biotechnologies · Tests: ClonoSEQ Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer NCT07057102n/a1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1 NCT04455282n/a2 sites📍 Cologne📍 Münster Heinrich-Heine University, Duesseldorf Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease NCT07023289Phase 248 sites📍 Huntsville📍 Fullerton📍 Los Angeles AbbVie · Tests: Telisotuzumab Adizutecan, Standard of Care Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients NCT07673861NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Marsden360 ctDNA test and GTAB review A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy NCT07375316Phase 24 sites📍 Guangzhou📍 Meizhou📍 Shantou Guangdong Association of Clinical Trials · Tests: Osimertinib + Sacituzumab Tirumotecan, Osimertinib Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma NCT06745076Phase 26 sites📍 Irvine📍 Palo Alto📍 Boston University of Washington · Tests: Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography Test A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer NCT07562490Phase 21 site📍 Shanghai Fudan University · Tests: FOLFOX, Folfox plus Bevacizumab Setting Up ctDNA Analysis on Archived Plasma Samples NCT07546578n/a1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: ctDNA Multiomics Tumor Evolution Model of NSCLC NCT05352035n/a1 site📍 Beijing Peking University People's Hospital PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Galleri® in the Medicare Population. NCT05673018NA72 sites📍 Fort Smith📍 Auburn📍 Davis GRAIL, Inc. · Tests: Multi-Cancer Early Detection Test (Galleri®) Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. NCT06167460n/a1 site📍 Ho Chi Minh City Gene Solutions T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer NCT07581496n/a2 sites📍 Basel📍 Lucerne University Hospital, Basel, Switzerland Tempus Small Cell Lung Cancer Observational Study (Sculptor) NCT05257551n/a11 sites📍 Los Alamitos📍 Aurora📍 Peoria Tempus AI · Tests: Observation ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST NCT05366816Phase 21 site📍 Miami University of Miami · Tests: Sunitinib, Regorafenib Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer NCT05788744NA5 sites📍 Aalborg📍 Aarhus📍 Copenhagen Copenhagen University Hospital at Herlev · Tests: ctDNA A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma NCT06610682EARLY Phase 12 sites📍 Baltimore📍 New York Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Plixorafenib, Retifanlimab A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases NCT06903325n/a1 site📍 Shanghai Fudan University · Tests: As an observational study, we did not intervene Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) NCT05512364Phase 3113 sites📍 Anderlecht📍 Brussels📍 Brussels European Organisation for Research and Treatment of Cancer … · Tests: Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy